Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA-YOUNG: Prosigna-guided Treatment in Premenopausal Early Breast Cancer
NCT07106632Phase 3Recruiting
- Sponsor
- Unicancer
- Start
- Jun 2026
- Primary completion
- Aug 2031
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Invasive Breast Cancer Free Survival at 120 months. Started Jun 2026; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07106632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106632.